```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:ssptayvv1621

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2          "Ask CAS" for self-help around the clock
 NEWS  3  FEB 27  New STN AnaVist pricing effective March 1, 2006
 NEWS  4  APR 04  STN AnaVist $500 visualization usage credit offered
 NEWS  5  MAY 10  CA/CAplus enhanced with 1900-1906 U.S. patent records
 NEWS  6  MAY 11  KOREAPAT updates resume
 NEWS  7  MAY 19  Derwent World Patents Index to be reloaded and enhanced
 NEWS  8  MAY 30  IPC 8 Rolled-up Core codes added to CA/CAplus and
                  USPATFULL/USPAT2
 NEWS  9  MAY 30  The F-Term thesaurus is now available in CA/CAplus
 NEWS 10  JUN 02  The first reclassification of IPC codes now complete in
                  INPADOC
 NEWS 11  JUN 26  TULSA/TULSA2 reloaded and enhanced with new search and
                  and display fields
 NEWS 12  JUN 28  Price changes in full-text patent databases EPFULL and PCTFULL
 NEWS 13  JUl 11  CHEMSAFE reloaded and enhanced
 NEWS 14  JUl 14  FSTA enhanced with Japanese patents
 NEWS 15  JUl 19  Coverage of Research Disclosure reinstated in DWPI
 NEWS 16  AUG 09  INSPEC enhanced with 1898-1968 archive

 NEWS EXPRESS  JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8
 NEWS X25      X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:26:45 ON 21 AUG 2006

=>
=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'REGISTRY' ENTERED AT 11:26:57 ON 21 AUG 2006
```

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 20 AUG 2006 HIGHEST RN 902860-89-3
DICTIONARY FILE UPDATES: 20 AUG 2006 HIGHEST RN 902860-89-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10600132-SAHA.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 11:27:23 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 169 TO ITERATE

100.0% PROCESSED 169 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 2601 TO 4159
PROJECTED ANSWERS: 1 TO 80

L2 1 SEA SSS SAM L1

=> search full l1
ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:sss
FULL SEARCH INITIATED 11:27:52 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 3210 TO ITERATE

100.0% PROCESSED 3210 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

L3 2 SEA SSS FUL L1

=> d l3 scan

L3 2 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Octanediamide, N-hydroxy-N'-(phenyl-4-t)- (9CI)
MF C14 H19 N2 O3 T



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 2 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Octanediamide, N-hydroxy-N'-phenyl- (9CI)
MF C14 H20 N2 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> file caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	167.82	168.03

FILE 'CAPLUS' ENTERED AT 11:28:31 ON 21 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 Aug 2006 VOL 145 ISS 9
FILE LAST UPDATED: 20 Aug 2006 (20060820/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

```
=> s l3
L4          258 L3

=> s l3 and polymorph?
            258 L3
         191933 POLYMORPH?
L5            4 L3 AND POLYMORPH?
```

```
=> s l4 and x-ray
       1531251 X
       1033733 RAY
        797654 X-RAY
                  (X(W)RAY)
L6           5 L4 AND X-RAY

=> s l4 and DSC
         57514 DSC
L7           0 L4 AND DSC

=> s l4 and differential
        314848 DIFFERENTIAL
L8           8 L4 AND DIFFERENTIAL

=> s l4 and methanol
        196715 METHANOL
L9           2 L4 AND METHANOL

=> s l4 and ethanol
        253287 ETHANOL
L10          2 L4 AND ETHANOL

=> s l4 and ?crystalliz?
        208204 ?CRYSTALLIZ?
L11          0 L4 AND ?CRYSTALLIZ?

=> s l4 and crystal
       1242517 CRYSTAL
L12          8 L4 AND CRYSTAL

=> s l4 and saha
          1301 SAHA
L13        173 L4 AND SAHA

=> s l4 and tablet
         44161 TABLET
L14          1 L4 AND TABLET

=> s l4 and gelatin
         68264 GELATIN
L15          1 L4 AND GELATIN

=> s l4 and capsule
         37606 CAPSULE
L16          0 L4 AND CAPSULE

=> s saha
L17       1301 SAHA

=> s l5 or l6 or l8 or l9 or l12 or l14 or l15
L18         22 L5 OR L6 OR L8 OR L9 OR L12 OR L14 OR L15
```

```
=> s l18 not py > 2003
       3149511 PY > 2003
L24            5 L18 NOT PY > 2003

=> d l24 ibib abs hitstr 1-
YOU HAVE REQUESTED DATA FROM 5 ANSWERS - CONTINUE? Y/(N):y

L24  ANSWER 1 OF 5  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2003:819069  CAPLUS
DOCUMENT NUMBER:          140:174966
TITLE:                    Differential regulation of the Sir2 histone
                          deacetylase gene family by inhibitors of class I and
                          II histone deacetylases
AUTHOR(S):                Kyrylenko, S.; Kyrylenko, O.; Suuronen, T.; Salminen,
                          A.
CORPORATE SOURCE:         Department of Neuroscience and Neurology, University
                          of Kuopio, Kuopio, 70211, Finland
SOURCE:                   Cellular and Molecular Life Sciences (2003), 60(9),
                          1990-1997
                          CODEN: CMLSFI; ISSN: 1420-682X
PUBLISHER:                Birkhaeuser Verlag
DOCUMENT TYPE:            Journal
LANGUAGE:                 English
AB   The Sir2 histone deacetylase gene family consists of seven mammalian
     sirtuins (SIRTs) which are NAD-dependent histone/protein deacetylases.
     Sir2 proteins regulate, for instance, genome stability by chromatin
     silencing in yeast.  In mammals, their function is still largely unknown.
     Due to the NAD+ dependency, Sir2 might be the link between metabolic
     activity and histone/protein acetylation.  Regulation of gene expression
     also seems to play an important role in Sir2 functions, since increasing
     the dosage of Sir2 genes increases genome stability in yeast and
     Caenorhabditis elegans.  We observed that the modification of histone/protein
     acetylation status by several class I and II histone deacetylase (HDAC)
     inhibitors induces differential changes in gene expression
     profiles of seven SIRT mRNAs in cultured neuronal cells.  SIRT2, SIRT4 and
     SIRT7 were upregulated, whereas SIRT1, SIRT5 and SIRT6 were downregulated
     by trichostatin A (TSA) and n-butyrate.  The upregulation of SIRT mRNAs
     was inhibited by actinomycin D.  Interestingly, the regulation of SIRT
     mRNAs was highly similar both in mouse Neuro-2a neuroblastoma cells and
     post-mitotic rat primary hippocampal and cerebellar granule neurons.
     Using a chromatin immunopptn. technique, we showed that the upregulation
     of SIRT2 expression with TSA is related to the hyperacetylation of
     DNA-bound histone H4 within the first 500 bp upstream of the transcription
     start site of the SIRT2 gene.  Chemical different types of HDAC inhibitors,
     such as TSA, apicidin, SAHA, M344 and n-butyrate induced remarkably
     similar responses in SIRT1-7 mRNA expression patterns.
     Differential responses in SIRT mRNA expression profiles indicate
     that the expression of the Sir2 family of genes is selectively regulated
     and dependent on histone/protein acetylation status.
IT   149647-78-9, SAHA
     RL: PAC (Pharmacological activity); BIOL (Biological study)
        (differential regulation of Sir2 histone deacetylase gene
        family by inhibitors of class I and II histone deacetylases)
RN   149647-78-9  CAPLUS
CN   Octanediamide, N-hydroxy-N'-phenyl- (9CI)  (CA INDEX NAME)
```



```
REFERENCE COUNT:          33     THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS
                                 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
```

L24 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:243259 CAPLUS
DOCUMENT NUMBER: 139:111230
TITLE: Susceptibility of multidrug resistance tumor cells to apoptosis induction by histone deacetylase inhibitors
AUTHOR(S): Castro-Galache, Maria D.; Ferragut, Jose A.; Barbera, Victor M.; Martin-Orozco, Elena; Gonzalez-Ros, Jose M.; Garcia-Morales, Pilar; Saceda, Miguel
CORPORATE SOURCE: Centro de Biologia Molecular y Celular, Universidad Miguel Hernandez, Elche, 03202, Spain
SOURCE: International Journal of Cancer (2003), 104(5), 579-586
CODEN: IJCNAW; ISSN: 0020-7136
PUBLISHER: Wiley-Liss, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The main goal of our study has been to analyze the efficiency of new anticancer drugs, specifically histone deacetylase inhibitors, in tumor cells bearing a multidrug resistance phenotype. We report that the histone deacetylase inhibitors, Trichostatin A and Suberoylanilide Hydroxamic Acid (SAHA), dramatically reduce cell viability and promote apoptosis in different drug-resistant cells, affecting in a much lesser extent to their parental drug-sensitive counterparts. The differential effects induced by Trichostatin A and SAHA between drug-sensitive and drug-resistant cells are reflected on the main characteristics of the resistant phenotype. Thus, reverse transcription-PCR and Western immunoblots confirm that both histone deacetylase inhibitors promote endogenous down-regulation of P-glycoprotein, which is overexpressed in the drug-resistant cells. Transfection of drug-sensitive cells with the P-glycoprotein cDNA ruled out the a priori possible association between apoptosis and down-regulation of P-glycoprotein induced by the histone deacetylase inhibitors. The results suggest a therapeutic potential of histone deacetylase inhibitors in the treatment of cancers with acquired resistance.

IT 149647-78-9, Suberoylanilide Hydroxamic Acid
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(susceptibility of multidrug resistance tumor cells to apoptosis induction by histone deacetylase inhibitors)
RN 149647-78-9 CAPLUS
CN Octanediamide, N-hydroxy-N'-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:381216 CAPLUS
DOCUMENT NUMBER: 135:131735
TITLE: 3-(4-Aroyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides, a new class of synthetic histone deacetylase inhibitors
AUTHOR(S): Massa, Silvio; Mai, Antonello; Sbardella, Gianluca; Esposito, Monica; Ragno, Rino; Loidl, Peter; Brosch, Gerald
CORPORATE SOURCE: Dipartimento Farmaco Chimico Tecnologico, Universita degli Studi di Siena, Siena, 53100, Italy
SOURCE: Journal of Medicinal Chemistry (2001), 44(13), 2069-2072

CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 135:131735

AB Novel 3-(4-aroyl-2-pyrrolyl)-N-hydroxy-2-propenamides are disclosed as a new class of histone deacetylase (HDAC) inhibitors. Three-dimensional structure-based drug design and conformational analyses into the histone deacetylase-like protein (HDLP) catalytic core suggested the synthesis and biol. evaluation of compds. 7a-h. Exptl. pKi values are in good agreement with VALIDATE predicted pKi values of new derivs. All compds. 7a-h show HDAC inhibitory activity in the micromolar range, with 7e as the most potent derivative (IC50 = 1.9 μM). The influence of the 4'-substituent in the aroyl moiety is not significant for the inhibitory activity, as all compds. 7a-g show IC50 values between 1.9 and 3.9 μM. Otherwise, the unsatd. chain linking the pyrrole ring to the hydroxamic acid group is clearly important for the anti-HDAC activity, the saturated analog 7h being 10-fold less active than the unsatd. counterpart 7a.

IT 149647-78-9
RL: BSU (Biological study, unclassified); BIOL (Biological study) (structure-based drug design of synthetic histone deacetylase inhibitors)

RN 149647-78-9 CAPLUS
CN Octanediamide, N-hydroxy-N'-phenyl- (9CI) (CA INDEX NAME)



Refs: 15

REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:185791 CAPLUS
DOCUMENT NUMBER: 134:204354
TITLE: Crystal structure of a histone deacetylase-like protein from Aquifex aeolicus and complexes with inhibitors
INVENTOR(S): Pavletich, Nikola; Finnin, Michael; Donigian, Jill; Richon, Victoria; Rifkind, Richard A.; Marks, Paul A.; Breslow, Ronald
PATENT ASSIGNEE(S): Sloan-Kettering Institute for Cancer Research, USA; Trustees of Columbia University in the City of New York
SOURCE: PCT Int. Appl., 329 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001018045	A1	20010315	WO 2000-US24700	20000908
WO 2001018045	C2	20021107		
W: CA, JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2383885	AA	20010315	CA 2000-2383885	20000908
EP 1212357	A1	20020612	EP 2000-968344	20000908
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				

JP 2003518923	T2	20030617	JP 2001-522267		20000908
US 2003013176	A1	20030116	US 2002-95109		20020308
PRIORITY APPLN. INFO.:			US 1999-152753P	P	19990908
			WO 2000-US24700	W	20000908

AB The present invention provides three-dimensional structural information of the histone deacetylase-like protein (HDLP) from the hyperthermophilic bacterium Aquifex aeolicus. HDLP shares 35.2% amino acid sequence identity with human histone deacetylase (HDAC1). The double mutant C75S/C77S of HDLP is used to facilitate the determination of three-dimensional structure of HDLP bound to a zinc atom at its zinc atom-binding site. The present invention further provides three-dimensional structural information of HDLP double mutant bound by inhibitor mols. (e.g., trichostatin A or suberoyl anilide hydroxamic acid). The three-dimensional structural information of the present invention is useful to design, isolate and screen deacetylase inhibitor compds. capable of inhibiting HDLP, HDAC family members, and HDLP-related mols. The invention also relates to nucleic acids encoding a mutant HDLP which facilitates the determination of the three-dimensional structure of HDLP in the presence of a zinc atom.

IT 149647-78-9D, complex with deacetylase protein
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(crystal structure of a histone deacetylase-like protein from Aquifex aeolicus and complexes with inhibitors)

RN 149647-78-9 CAPLUS

CN Octanediamide, N-hydroxy-N'-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1999:596349 CAPLUS

DOCUMENT NUMBER: 131:334011

TITLE: Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors

AUTHOR(S): Finnin, Michael S.; Donigian, Jill R.; Cohen, Alona; Richon, Victoria M.; Rifkind, Richard A.; Marks, Paul A.; Breslow, Ronald; Pavletich, Nikola P.

CORPORATE SOURCE: Cellular Biochemistry and Biophsyics Program and Howard Hughes Medical Institute, Cell Biology Program, Memorial Sloan-Kettering Cancer Center, New York, NY, 10021, USA

SOURCE: Nature (London) (1999), 401(6749), 188-193
CODEN: NATUAS; ISSN: 0028-0836

PUBLISHER: Macmillan Magazines

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Histone deacetylases (HDACs) mediate changes in nucleosome conformation and are important in the regulation of gene expression. HDACs are involved in cell-cycle progression and differentiation, and their deregulation is associated with several cancers. HDAC inhibitors, such as trichostatin A (TSA) and suberoylanilide hydroxamic acid (SAHA), have anti-tumor effects, as they can inhibit cell growth, induce terminal differentiation and prevent the formation of tumors in mice models, and they are effective in the treatment of promyelocytic leukemia. Here we describe the structure of the histone deacetylase catalytic core, as revealed by the crystal structure of a homolog from the hyperthermophilic bacterium Aquifex aeolicus, that shares 35.2% identity

with human HDAC1 over 375 residues, deacetylates histones in vitro and is inhibited by TSA and SAHA. The deacetylase, deacetylase-TSA and deacetylase-SAHA structures reveal an active site consisting of a tubular pocket, a zinc-binding site and two Asp-His charge-relay systems, and establish the mechanism of HDAC inhibition. The residues that make up the active site and contact the inhibitors are conserved across the HDAC family. These structures also suggest a mechanism for the deacetylation reaction and provide a framework for the further development of HDAC inhibitors as antitumor agents.

IT 149647-78-9
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(crystal structures of histone deacetylase homolog bound to trichostatin A and suberoylanilide hydroxamic acid)

RN 149647-78-9 CAPLUS

CN Octanediamide, N-hydroxy-N'-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT